Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting
26 avr. 2023 18h41 HE
|
Tempest Therapeutics
BRISBANE, Calif., April 26, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting
17 avr. 2023 09h00 HE
|
Tempest Therapeutics
BRISBANE, Calif., April 17, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
Tempest Reports Year End 2022 Financial Results and Provides Business Update
22 mars 2023 17h26 HE
|
Tempest Therapeutics
Positive monotherapy and combination therapy data from Phase 1 trial of first clinical program, TPST-1120, announced in an oral presentation at ASCO 2022 TPST-1120 randomized combination study in...
Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting
15 mars 2023 16h05 HE
|
Tempest Therapeutics
BRISBANE, Calif., March 15, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting
14 mars 2023 16h30 HE
|
Tempest Therapeutics
BRISBANE, Calif., March 14, 2023 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both targeted...
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference
22 nov. 2022 16h05 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company focused on developing first-in-class therapeutics that...
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer
10 nov. 2022 09h00 HE
|
Tempest Therapeutics
TPST-1120 Late-breaking Poster Presentation at SITC Annual MeetingSecond Poster Presentation Demonstrates that Dual Blockade of EP2 and EP4 PGE2 Receptors with TPST-1495 is an Optimal Approach for...
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update
08 nov. 2022 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting
02 nov. 2022 08h00 HE
|
Tempest Therapeutics
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage oncology company developing first-in-class1 therapeutics that combine both...
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit
06 oct. 2022 08h00 HE
|
Tempest Therapeutics
Dara Burdette, Ph.D., Tempest Senior Director of Discovery Research, to Chair “New Approaches to Solid Tumor Targeting” SessionNicholas DeVito, M.D, Duke University School of Medicine, to present...